Abstract:Abstract Bladder cancer remains a leading cause of cancer death worldwide and is associated with substantial impacts on patient quality of life, morbidity, mortality, and cost to the healthcare system. Gross hematuria frequently precedes the diagnosis of bladder cancer. Non-muscle-invasive bladder cancer (NMIBC) is managed initially with transurethral resection of a bladder tumor (TURBT), followed by a risk stratified approach to adjuvant intravesical therapy (IVe), and is associated with an overall survival of 90%. However, cure rates remain lower for muscle invasive bladder cancer (MIBC) owing to a variety of factors. NMIBC and MIBC groupings are heterogeneous and have unique pathological and molecular characteristics. Indeed, The Cancer Genome Atlas project identified genetic drivers and luminal and basal molecular subtypes of MIBC with distinct treatment responses. For NMIBC, IVe immunotherapy (primarily BCG) is the gold standard treatment for high grade and high risk NMIBC to reduce or prevent both recurrence and progression after initial TURBT; novel trials incorporate immune checkpoint inhibitors. IVe gene therapy and combination IVe chemotherapy have recently been completed, with promising results. For localized MIBC, essential goals are improving care and reducing morbidity following cystectomy or bladder preserving strategies. In metastatic disease, advances in understanding of the genomic landscape and tumor microenvironment have led to the implementation of immune checkpoint inhibitors, targeted treatments, and antibody-drug conjugates. Defining better selection criteria to identify the patients most likely to benefit from a specific treatment is an urgent need.

Present Challenges and Future Directions

Bladder Cancer: Current Challenges and Future Directions

Digital and Computational Pathology Applications in Bladder Cancer: Novel Tools Addressing Clinically Pressing Needs

Advances in Diagnosis and Therapy for Bladder Cancer

Advancements in bladder cancer detection: a comprehensive review on liquid biopsy and cell-free DNA analysis

Advances in bladder cancer biology and therapy

Advances in diagnosis and treatment of bladder cancer

Targeted therapies in bladder cancer: signaling pathways, applications, and challenges

Advances in basic research, clinical diagnosis and treatment of bladder cancer in 2022

Featured Review Article Biomarkers for bladder cancer management: present and future

Modeling bladder cancer in the laboratory: Insights from patient-derived organoids

Therapeutic Targets and Predictive Markers of Treatment Efficacy of Bladder Cancer

The Current Progress and Future Options of Multiple Therapy and Potential Biomarkers for Muscle-Invasive Bladder Cancer

Preclinical models for bladder cancer therapy research

Integrating the PD-L1 Prognostic Biomarker in Non-Muscle Invasive Bladder Cancer in Clinical Practice—A Comprehensive Review on State-of-the-Art Advances and Critical Issues

Bladder Cancer-Associated Microbiota: Recent Advances and Future Perspectives

New Perspectives on the Role of Liquid Biopsy in Bladder Cancer: Applicability to Precision Medicine

Abstract IA012: Novel approaches to the management of non-muscle invasive bladder cancer

Germline Prognostic Markers for Urinary Bladder Cancer: Obstacles and Opportunities.

Blood-based liquid biopsy: insights into early detection, prediction, and treatment monitoring of bladder cancer